Cefoperazone Sodium
FDA-approved product (injectable, injection), marketed as Cefobid, Cefobid In Plastic Container.
- Registered studies
- 16
- Lab records
- 5
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Third-generation cephalosporins
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01DD12
Repurposing investigation
Cefoperazone Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA64.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli94.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae98.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
16registered studies name this medicine, for any condition. See them below.
Experimental
- E. coli: measured active in 1 of 1 lab record
- K. pneumoniae: measured active in 2 of 4 lab records
Show the 5 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Cefoperazone Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells41.4% AI-predicted activityagainst K. pneumoniae10 registered studies
- Ergotamine TartrateExisting use: Headache, Migraine disorder41.3% AI-predicted activityagainst K. pneumoniae10 registered studies
- InavolisibExisting use: Breast cancer, Breast neoplasm41.2% AI-predicted activityagainst K. pneumoniae36 registered studies
- Rimegepant SulfateExisting use: Migraine disorder40.9% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Pasireotide PamoateExisting use: Acromegaly, Pituitary-dependent Cushing's disease40.9% AI-predicted activityagainst K. pneumoniae1 registered study
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia40.9% AI-predicted activityagainst K. pneumoniae41 registered studies
- Avatrombopag MaleateExisting use: Hemorrhage, Liver disease, Thrombocytopenia40.8% AI-predicted activityagainst K. pneumoniae6 registered studies
- LinagliptinExisting use: Diabetes mellitus, Type 2 diabetes mellitus40.6% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Rocuronium BromideExisting use: Other quaternary ammonium compounds40.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- BiotinExisting use: Anemia (phenotype), Chronic kidney disease, Iron deficiency anemia and 1 more40.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- BuprenorphineExisting use: Chronic pain, Drug dependence, Opioid dependence and 4 more40.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Vinorelbine TartrateExisting use: Cancer, Neoplasm40.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections
NCT00360607 · start 2004-07
Registered record
- Registry ID
- NCT00360607
- Conditions
- Infection
- Interventions
- Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.; Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited; Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.; Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-07
- Completion
- 2005-04
- Enrolment
- 307
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfectionInterventionMagnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.; Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited; Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.; Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.PhasePhase 4Registry statusCompleted